Pharsight

Mekinist patents expiration

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(3 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(1 year, 8 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(2 years from now)

US7378423

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Nov, 2027

(4 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(7 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(7 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(7 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9155706

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US8580304

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US9271941

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US9399021

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(10 years from now)

Mekinist is owned by Novartis.

Mekinist contains Trametinib Dimethyl Sulfoxide.

Mekinist has a total of 18 drug patents out of which 0 drug patents have expired.

Mekinist was authorised for market use on 29 May, 2013.

Mekinist is available in tablet;oral dosage forms.

Mekinist can be used as mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy, mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test, mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection.

The generics of Mekinist are possible to be released after 02 March, 2034.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 16, 2030
New Indication (I) Jun 22, 2025
Pediatric Exclusivity (PED) Dec 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...

Dosage: TABLET;ORAL

More Information on Dosage

MEKINIST family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic